Search Results

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida.

Insulet Corporation released its 2023 Sustainability Report, which describes key accomplishments in environmental, social, and governance areas in 2023.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that management will present at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:00 a.m.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System, including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well as the limited market release of the Omnipod 5 App for iPhone.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced financial results for the three months ended March 31, 2024.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024.

Insulet Corporation announced the following appointments to the Company’s Board of Directors, effective January 18.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, presented positive results from its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System.